Rob Readnour

Dr. Readnour currently serves as Executive Chairman of In the Bowl Animal Health, an animal health company that is developing an in-feed technology providing pet owners with a convenient alternative to current methods of drug administration. Dr. Readnour also currently serves as Chairman and CEO of Borah, a company that is developing small molecule approaches focused on leveraging the unique chemical properties of boron chemistry in animal health. Dr. Readnour also currently serves on or has visitation rights to the following companies: Advanced Animal Diagnostics, a commercial-stage animal health company developing diagnostic tests to help livestock producers diagnose illness, predict performance and eliminate the overuse of antibiotics in cattle, AN2 Therapeutics, a biopharmaceutical company developing medicines for infectious diseases, Exubrion, an animal health company developing a radiosynoviorthesis product to treat chronic osteoarthritis in dogs, and TARGAN, a poultry vaccine delivery device company developing a novel, high-throughput spray system to individually vaccinate post-hatch chicks.

Prior to joining MGP, Dr. Readnour worked at Elanco Animal Health for 27 years. During his Elanco tenure, he held several senior management positions in which he was responsible for developing and executing Elanco’s Research and Development strategies for entering several new business areas (companion animal pharmaceuticals, vaccines and enzymes). Dr. Readnour played an important role in Elanco’s acquisition and integration of Novartis Animal Health, Lohmann Animal Health, ChemGen and Janssen Animal Health. Within Elanco, Dr. Readnour led several initiatives to transform Research and Development through the piloting of new approaches to developing animal health products. He pioneered a lean product development model which allowed Elanco to enter new areas of business without significant capital investment. He led initial efforts for Elanco to invest in early stage companies and partner with external funding sources to develop products with minimal initial investment from Elanco. Dr. Readnour served as a member of the Food and Agriculture Section of Bio International Board and as an External Advisory Board member for University of Illinois Animal Science Department.

Prior to entering management in Elanco, Dr. Readnour was an internationally recognized expert on animal health product development, analytical chemistry, human food safety and drug residues with 11 publications and 14 external presentations. Throughout his career, Dr. Readnour was responsible for the development and commercialization of 10 animal health products. Dr. Readnour received his PhD in Analytical Chemistry from University of Illinois in 1990.